Noteworthy, the two KDM5C subgroups showed significant changes in NANOG expression in the subset of patients without epilepsy (Figure S3B) or with the wild-type IDH1/2 genotype (Figure S3C) or with MGMT methylation (Figure S3D), while significant OCT4 change was found in the subset of patients with the wild-type IDH1/2 genotype (Figure S3E). This evidence concerns the gene NANOG and epilepsy.